Influenza Vaccine Enhancement Patch: Phase I started

Intercell began an open-label, European Phase I trial to compare its Influenza VEP in combination with GlaxoSmithKline's H5N1 antigen vs. GSK's licensed Pumarix H5N1 vaccine in 300 healthy adults. Th...